122 related articles for article (PubMed ID: 11154039)
1. Bilateral transient hearing loss associated with vincristine therapy: case report.
Aydogdu I; Ozturan O; Kuku I; Kaya E; Sevinc A; Yildiz R
J Chemother; 2000 Dec; 12(6):530-2. PubMed ID: 11154039
[TBL] [Abstract][Full Text] [Related]
2. [The efficacy and safety of PAD and VAD regimens for untreated multiple myeloma].
Zhao Y; Dou LP; Wang SH; Bo J; Wang QS; Huang WR; Jing Y; Gao CJ; Li HH; Zhu HY; Han XP; Yu L
Zhonghua Nei Ke Za Zhi; 2010 Sep; 49(9):762-4. PubMed ID: 21092447
[TBL] [Abstract][Full Text] [Related]
3. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
4. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
5. A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma.
Cook G; Clark RE; Morris TC; Robertson M; Lucie NP; Anderson S; Paul J; Franklin IM
Br J Haematol; 2004 Sep; 126(6):792-8. PubMed ID: 15352982
[TBL] [Abstract][Full Text] [Related]
6. [Adverse effects of PAD and VAD regimens in multiple myeloma patients].
Zhao Y; Jing Y; Bo J; Li HH; Wang SH; Huang WR; Zhu HY; Han XP; Dou LP; Wang FF; Li F; Gao CJ; Wang QS; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):1027-30. PubMed ID: 20723322
[TBL] [Abstract][Full Text] [Related]
7. Treatment of refractory multiple myeloma with vincristine, adriamycin, dexamethasone, and with repeated application of cyclophosphamide (C-VAD).
Adam Z; Elbl L; Vorlicek J; Hájek R; Hájek D; Hejlová N; Králová E; Novotná H
Acta Med Austriaca; 1994; 21(4):111-5. PubMed ID: 7871966
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of rhIL-6 (interleukin-6) prior to and concurrently with VAD (vincristine, doxorubicin and dexamethasone) chemotherapy for patients with multiple myeloma.
Young RI; Ranson M; Chang J; Lord B; Testa N; Scarffe JH
Eur J Cancer; 1997 Feb; 33(2):307-11. PubMed ID: 9135507
[TBL] [Abstract][Full Text] [Related]
9. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.
Hussein MA; Wood L; Hsi E; Srkalovic G; Karam M; Elson P; Bukowski RM
Cancer; 2002 Nov; 95(10):2160-8. PubMed ID: 12412170
[TBL] [Abstract][Full Text] [Related]
10. [Lower cardiotoxicity of adriamycin during continuous administration in patients with refractory multiple myeloma treated with cyclophosphamide, vincristine, adriamycin and dexamethasone (C-VAD)].
Adam Z; Elbl L; Vorlícek J; Hájek R; Tomíska M; Hejlová N; Králová E; Novotná H
Vnitr Lek; 1994 Aug; 40(8):506-12. PubMed ID: 7941437
[TBL] [Abstract][Full Text] [Related]
11. VAD-based regimens as primary treatment for multiple myeloma.
Alexanian R; Barlogie B; Tucker S
Am J Hematol; 1990 Feb; 33(2):86-9. PubMed ID: 2301376
[TBL] [Abstract][Full Text] [Related]
12. Assessment of early paraprotein response to vincristine-doxorubicin-dexamethasone chemotherapy may help guide therapy in multiple myeloma.
Ross DM; To LB; Horvath N
Intern Med J; 2004; 34(9-10):576-8. PubMed ID: 15482273
[TBL] [Abstract][Full Text] [Related]
13. [Improved prognosis of generalized AL-amyloidosis in a patient with multiple myeloma treated according to the VAD protocol].
Sarkisova IA; Rameev VV; Kozlovskaia LV; Andreeva NE
Ter Arkh; 2003; 75(8):81-2. PubMed ID: 14520860
[No Abstract] [Full Text] [Related]
14. Potential value of vintristine-adriamycin-dexamethasone combination chemotherapy (VAD) in refractory and rapidly progressive myeloma.
Collin R; Greaves M; Preston FE
Eur J Haematol; 1987 Sep; 39(3):203-8. PubMed ID: 3678471
[TBL] [Abstract][Full Text] [Related]
15. Ischemic heart disease associated with vincristine and doxorubicin chemotherapy.
Calvo-Romero JM; Fernández-Soria-Pantoja R; Arrebola-Garcia JD; Gil-Cubero M
Ann Pharmacother; 2001 Nov; 35(11):1403-5. PubMed ID: 11724093
[TBL] [Abstract][Full Text] [Related]
16. Effective treatment of advanced multiple myeloma refractory to alkylating agents.
Barlogie B; Smith L; Alexanian R
N Engl J Med; 1984 May; 310(21):1353-6. PubMed ID: 6546971
[TBL] [Abstract][Full Text] [Related]
17. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
Weiser MA; Cabanillas ME; Konopleva M; Thomas DA; Pierce SA; Escalante CP; Kantarjian HM; O'Brien SM
Cancer; 2004 Mar; 100(6):1179-85. PubMed ID: 15022284
[TBL] [Abstract][Full Text] [Related]
18. [Ambulatory therapy of multiple myeloma with vincristine, adriamycin and dexamethasone].
Egerer G; Hegenbart U; Salwender H; Hahn U; Haas R; Goldschmidt H; Hunstein W
Dtsch Med Wochenschr; 1997 Apr; 122(17):531-5. PubMed ID: 9190299
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and toxicity of VAD in the treatment of myeloma and related disorders.
Sheehan T; Judge M; Parker AC
Scand J Haematol; 1986 Nov; 37(5):425-8. PubMed ID: 3810040
[TBL] [Abstract][Full Text] [Related]
20. [Could the VAD protocol be the first line therapy for multiple myeloma in subSaharan Africa? The Brazzaville experience].
Dokekias AE
Sante; 2011; 21(3):169-70. PubMed ID: 22396958
[No Abstract] [Full Text] [Related]
[Next] [New Search]
